US 12,331,130 B2
DDR1 antibodies and uses thereof
Ningyan Zhang, Houston, TX (US); Zhiqiang An, Houston, TX (US); Hui Deng, Houston, TX (US); Xiujie Sun, Washington, DC (US); and Rong Li, Washington, DC (US)
Assigned to THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US); and THE GEORGE WASHINGTON UNIVERSITY, Washington, DC (US)
Filed by THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US); and THE GEORGE WASHINGTON UNIVERSITY, Washington, DC (US)
Filed on Feb. 28, 2023, as Appl. No. 18/176,072.
Application 18/176,072 is a continuation of application No. 17/757,510, previously published as PCT/US2020/065618, filed on Dec. 17, 2020.
Claims priority of provisional application 62/949,300, filed on Dec. 17, 2019.
Prior Publication US 2023/0235078 A1, Jul. 27, 2023
Int. Cl. C07K 16/30 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C12N 15/63 (2006.01)
CPC C07K 16/2896 (2013.01) [A61P 35/00 (2018.01); C12N 15/63 (2013.01); C07K 2317/20 (2013.01); C07K 2317/565 (2013.01)] 13 Claims
 
1. A monoclonal antibody or antigen-binding fragment thereof that specifically binds to discoidin domain receptor 1 (DDR1) protein, comprising:
a light chain variable region comprising an LC-CDR1, an LC-CDR2 and an LC-CDR3,
wherein
the amino acid sequence of the LC-CDR1 comprises the amino acid sequence of amino acids 24-34 of SEQ ID NO: 150,
the amino acid sequence of the LC-CDR2 comprises the amino acid sequence of amino acids 50-56 of SEQ ID NO: 150,
the amino acid sequence of the LC-CDR3 comprises the amino acid sequence of amino acids 89-97 of SEQ ID NO: 150,
and a heavy chain variable region comprising an HC-CDR1, an HC-CDR2, and an HC-CDR3, wherein
the amino acid sequence of the HC-CDR1 comprises the amino acid sequence of amino acids 31-35 of SEQ ID NO: 152,
the amino acid sequence of the HC-CDR2 comprises the amino acid sequence of amino acids 50-65 of SEQ ID NO: 152, and
the amino acid sequence of the HC-CDR3 comprises the amino acid sequence of amino acids 98-110 of SEQ ID NO: 152,
and wherein the monoclonal antibody is a rabbit, a chimeric or a humanized antibody,
and wherein the monoclonal antibody is not a bispecific antibody.